TransCode Therapeutics Inc (RNAZ) concluded trading on Thursday at a closing price of $5.50, with 10.81 million shares of worth about $59.46 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.09% during that period and on January 23, 2025 the price saw a gain of about 57.59%. Currently the company’s common shares owned by public are about 0.70M shares, out of which, 0.70M shares are available for trading.
Stock saw a price change of 72.41% in past 5 days and over the past one month there was a price change of 42.86%. Year-to-date (YTD), RNAZ shares are showing a performance of 63.20% which decreased to -80.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.66 but also hit the highest price of $66.33 during that period. The average intraday trading volume for TransCode Therapeutics Inc shares is 64.28K. The stock is currently trading 53.40% above its 20-day simple moving average (SMA20), while that difference is down -23.56% for SMA50 and it goes to -70.35% lower than SMA200.
TransCode Therapeutics Inc (NASDAQ: RNAZ) currently have 0.70M outstanding shares and institutions hold larger chunk of about 11.19% of that.
The stock has a current market capitalization of $3.83M and its 3Y-monthly beta is at 0.79. It has posted earnings per share of -$265.83 in the same period. It has Quick Ratio of 1.58 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNAZ, volatility over the week remained 60.28% while standing at 24.29% over the month.
Analysts are in expectations that TransCode Therapeutics Inc (RNAZ) stock would likely to be making an EPS of -3.21 in the current quarter, while forecast for next quarter EPS is 0 and it is -4.37 for next year. For the current quarter EPS, analysts have given the company a lowest target -3.21 which is -3.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -627.33 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 99.86% while it is estimated to increase by 8.19% in next year.
